INL researchers are part of the consortium behind BIOCELLPHE, a pioneering project focused on advancing cancer diagnostics and personalised medicine. This innovative European-funded project is at the forefront of scientific and technological innovation, introducing a groundbreaking technology for identifying proteins as diagnostic biomarkers at the single-cell level. This new approach offers multiplexing capabilities, portability and enhanced sensitivity. Alexandra Teixeira, research fellow at the Medical Devices group, highlights that “BIOCELLPHE is pioneering the use of engineered bacteria to recognise and bind with high specificity to protein targets on the surface of circulating tumour cells, or CTCs, which are key players in cancer metastasis.” This specific binding of engineered bacteria to CTCs subsequently triggers the production of molecules (Raman reporters), which can be detectable with high sensitivity using surface-enhanced Raman scattering (SERS). More specifically, SERS uses plasmonic nanoparticles to enhance Raman signals, allowing ultrasensitive analysis and detection at the single molecule level. The pathological role of CTCs in cancer metastasis is not completely understood due to the lack of effective analytical tools and remains an area that needs further exploration. BIOCELLPHE addresses this gap by developing new tools for the phenotypic identification of CTCs at the single-cell level, with high-throughput and multiplexing […]
Read more
